Biotechnology
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 - Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...
2022-11-11 08:30
2569
Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting
SUZHOU, China, Nov. 11, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented...
2022-11-11 08:00
3355
YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer, to...
2022-11-10 22:30
2812
CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO
WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment ofJeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him mo...
2022-11-10 21:00
2518
Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...
2022-11-10 19:02
2019
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715
SUZHOU, China, Nov. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been s...
2022-11-10 09:12
2150
Monash University Implements Antibody Discovery Application by Utilizing the Berkeley Lights Beacon® Platform
EMERYVILLE, Calif. and MELBOURNE, Australia, Nov. 10, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Monash University, one ofAustralia's leading universities, has implemented the use of the Berkeley Lights Beacon® system and Opto® Plas...
2022-11-10 07:57
2374
ANGUS ACQUIRES EXPRESSION SYSTEMS, LLC
Expression Systems is a leading supplier of innovative cell culture media, baculovirus molecular reagents and cell lines used in advanced biological-based therapeutics BUFFALO GROVE, Ill. and DAVIS, Calif., Nov. 10, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading gl...
2022-11-10 04:57
3403
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ --...
2022-11-09 23:32
2622
Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update
SUZHOU, China, Nov. 9, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, announces that the management ...
2022-11-09 21:09
3318
Strong business performance in 9M/2022: Exyte increases order intake, sales, and profitability
* Order intake up by more than 25% year-on-year, marking a new 9M-high with €6.5 billion * Sales volume increased by almost 60% to €5.3 billion * Strong increase in sales in all three business segments * Adjusted EBIT increased by 73% to €308 million; adjusted EBITDA rose by 70% to €340 mi...
2022-11-09 18:40
2924
Siemens Healthineers to demonstrate the remote capabilities of Corindus CorPath GRX Robotic System using Mentice VIST ® Simulator
GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ -- Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China is showcasing the remote capabilities of the Corindus CorPath GRX Robotic PCI system by using the Mentice VIS...
2022-11-09 16:52
2807
TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis
INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and the discovery ...
2022-11-09 06:00
2083
ScoliCare Opens its First Clinic in the US
New service will treat scoliosis and hyperkyphosis patients in Florida NAPLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- ScoliCare, Australia's largest provider of non-surgical scoliosis and hyperkyphosis treatment and leading worldwide brace manufacturer (ScoliBrace®), today announced the opening of i...
2022-11-08 23:27
2134
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress
* Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled * HTBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated to begin by year-end * CAB-CTLA-4 (HTBA3071) Pha...
2022-11-08 23:08
2511
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
* The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary * Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains * The trial showed no benefit for a bivalent vaccin...
2022-11-08 21:00
3420
Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria
SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...
2022-11-08 20:25
1677
MGI Partners with ALACRiS Theranostics to Open New Customer Experience Center in Germany
BERLIN, Nov. 8, 2022 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, today announced the launch of its new Customer Experience Center (CEC) inBerlin, Germany. The CEC is located at ALACRiS Theranostics GmbH (ALACRiS)'s facility. ALACRiS Therano...
2022-11-08 19:37
1603
EIT Health's Venture Centre of Excellence Names ProductLife Group as Privileged Partner for Regulatory & Compliance
* The ambitious EU initiative has already secured 2 billion euros of co-investment capabilities and has supported 60 innovative Biotech, Medtech & digital health start-ups to get to market or expand into new territories. * EIT Health, co-operator of the Venture Centre of Excellence alongside t...
2022-11-08 16:00
2405
BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston
BOSTON, Nov. 8, 2022 /PRNewswire/ -- Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea), was a featured speaker at a plenary session of the RNA Leaders CongressUSA in Boston, MA, on October 18th, 2022. Dr Ryu focused on the new efficacy data of their leading compound,BMD-001, derived...
2022-11-08 15:59
1720
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 298 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 294 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 278 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
9561
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
6126
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
6011
